Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES2 | Q9H7Z7 | 9/20 | 0.76 |
| ▸ | LMNA | P02545 | 3/20 | 0.76 |
| ▸ | HTT | P42858 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.51 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Artemotil SCHEMBL1648554 | 1.00 | PTGES2 (0.76) | PTGES2LMNAHTTALDH1A1CYP3A4 | |
| Artemotil SCHEMBL16710281 | 1.00 | PTGES2 (0.76) | PTGES2LMNAHTTALDH1A1CYP3A4 | |
| Artemotil SCHEMBL17156474 | 1.00 | PTGES2 (0.76) | PTGES2LMNAHTTALDH1A1CYP3A4 | |
| Artemotil SCHEMBL16404848 | 1.00 | PTGES2 (0.76) | PTGES2LMNAHTTALDH1A1CYP3A4 | |
| Artemotil SCHEMBL60335 | 1.00 | PTGES2 (0.76) | PTGES2LMNAHTTALDH1A1CYP3A4 | |
| Artemotil SCHEMBL18422062 | 1.00 | PTGES2 (0.76) | PTGES2LMNAHTTALDH1A1CYP3A4 | |
| Artemotil SCHEMBL10041607 | 1.00 | PTGES2 (0.76) | PTGES2LMNAHTTALDH1A1CYP3A4 | |
| Artemotil SCHEMBL60336 | 1.00 | PTGES2 (0.76) | PTGES2LMNAHTTALDH1A1CYP3A4 | |
| Artemotil SCHEMBL4539927 | 1.00 | PTGES2 (0.76) | PTGES2LMNAHTTALDH1A1CYP3A4 | |
| Artemotil SCHEMBL18950949 | 1.00 | PTGES2 (0.76) | PTGES2LMNAHTTALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 611 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250375399-A1 | LIQUID INJECTABLE COMPOSITION | AMATERASU LIFESCIENCES LLP (IN) | 2025-12-11 | — | — | US | claimed |
| US-12448559-B1 | Puddle job with delayed setting of resin via a polymerization reaction with an activator | HALLIBURTON ENERGY SERVICES, INC. (US) | 2025-10-21 | — | — | US | claimed |
| WO-2025133260-A1 | INHIBITORS OF PLASMODIA REMODELING ENZYMES | UNIVERSITÄT REGENSBURG, IN VERTRETUNG DES FREISTAATES BAYERN (DE) | 2025-06-26 | — | — | WO | claimed |
| EP-4574143-A1 | INHIBITORS OF PLASMODIA REMODELING ENZYMES | Universität Regensburg (DE) | 2025-06-25 | — | — | EP | claimed |
| EP-3990434-B1 | 1,1'-[1,3-(5-METHOXY)PHENYLENEBIS(METHYLENE)]BIS[4,5-DIPHENYL-1H-IMIDAZOLE] AND SIMILAR COMPOUNDS FOR THE TREATMENT OF MALARIA | UNIV NANYANG TECH (SG) | 2025-06-25 | — | — | EP | claimed |
| US-20250064775-A1 | SELECTIVE ELIMINATION OF SENESCENT CELLS BY FERROPTOSIS INDUCTION | TRUSTEES OF TUFTS COLLEGE | 2025-02-27 | — | — | US | claimed |
| US-20230380428-A1 | BIODEGRADABLE CLEANING PRODUCTS, METHODS OF PRODUCTION, AND THEIR COMPOSITIONS | SUSTAINABLE COMMUNITY DEV LLC (US) | 2023-11-30 | — | — | US | claimed |
| WO-2023133414-A2 | SELECTIVE ELIMINATION OF SENESCENT CELLS BY FERROPTOSIS INDUCTION | TRUSTEES OF TUFTS COLLEGE (US) | 2023-07-13 | — | — | WO | claimed |
| US-20230094952-A1 | Method for Culturing Hematopoietic Stem Cells | Sumitomo Pharma Co., Ltd. (JP) | 2023-03-30 | — | — | US | claimed |
| US-20230000884-A1 | COMBINATION THERAPY FOR TREATING COVID-19 | Luckwel Pharmaceuticals Inc. | 2023-01-05 | — | — | US | claimed |
| EP-2046339-A1 | RHO/ROCK/P13/AKT KINASE INHIBITORS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH PROTOZOAN PARASITES | Université Pierre et Marie Curie (Paris VI) (FR) | 2009-04-15 | — | — | EP | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| EP-1891958-A1 | Rho/Rock/PI3/Akt kinase inhibitors for the treatment of diseases associated with protozoan parasites. | UNIVERSITE PIERRE ET MARIE CURIE (PARIS VI) (FR) | 2008-02-27 | — | — | EP | claimed |
| WO-2008015001-A1 | RHO/ROCK/P13/AKT KINASE INHIBITORS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH PROTOZOAN PARASITES | UNIVERSITE PIERRE ET MARIE CURIE-PARIS VI (FR) | 2008-02-07 | — | — | WO | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20040047908-A1 | Modified released formulations containing a hypnotic agent | LEMMENS JACOBUS M (NL) | 2004-03-11 | — | — | US | claimed |
| US-20030054041-A1 | Modified release formulations containing a hypnotic agent | SYNTHON IP INC. | 2003-03-20 | — | — | US | claimed |
| EP-1272181-A2 | MODIFIED RELEASE FORMULATIONS CONTAINING A HYPNOTIC AGENT | Synthon B.V. (NL) | 2003-01-08 | — | — | EP | claimed |
| WO-2001078725-A2 | MODIFIED RELEASE FORMULATIONS CONTAINING A HYPNOTIC AGENT | SYNTHON B.V. (NL) | 2001-10-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030054041-A1 | Modified release formulations containing a hypnotic agent | CRH, HTR7, MCHR1 | PTGES2 3490/4885LMNA 3552/4885HTT 276/4885 |
| US-20230094952-A1 | Method for Culturing Hematopoietic Stem Cells | HCLS1, KIT, MCL1 | PTGES2 3102/4885LMNA 4664/4885HTT 2455/4885 |
| US-20250064775-A1 | SELECTIVE ELIMINATION OF SENESCENT CELLS BY FERROPTOSIS INDUCTION | AIFM2, HMOX1, DDIT3 | PTGES2 673/4885LMNA 1749/4885HTT 1314/4885 |
| US-20040047908-A1 | Modified released formulations containing a hypnotic agent | CRH, HTR7, MCHR1 | PTGES2 3425/4885LMNA 3534/4885HTT 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.